Azuma Yuichiro, Tamiya Motohiro, Shiroyama Takayuki, Osa Akio, Takeoka Sawa, Morishita Naoko, Suzuki Hidekazu, Okamoto Norio, Hirashima Tomonori, Kawase Ichiro
Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Japan.
Intern Med. 2015;54(22):2911-3. doi: 10.2169/internalmedicine.54.3243. Epub 2015 Nov 15.
It has recently been shown that nanoparticle albumin-bound paclitaxel (nab-PAC)+carboplatin (CBDCA) provides a favorable overall response rate in non-small cell lung cancer. This is the first case report of nab-PAC+CBDCA therapy in small cell lung cancer (SCLC). Our patient was a 72-year-old man with stage IV SCLC combined with squamous cell carcinoma and interstitial lung disease (ILD). We administered nab-PAC+CBDCA as a second-line chemotherapy. A partial response was evident after two cycles of chemotherapy, and no serious side effects occurred. The progression-free survival was 15 weeks. Second-line chemotherapy using nab-PAC+CBDCA was effective and well tolerated in an SCLC patient with ILD.
最近研究表明，纳米白蛋白结合型紫杉醇（nab-PAC）联合卡铂（CBDCA）在非小细胞肺癌中具有良好的总体缓解率。这是纳米白蛋白结合型紫杉醇联合卡铂治疗小细胞肺癌（SCLC）的首例病例报告。我们的患者是一名72岁男性，患有IV期小细胞肺癌合并鳞状细胞癌和间质性肺疾病（ILD）。我们给予纳米白蛋白结合型紫杉醇联合卡铂作为二线化疗。两个周期化疗后出现明显部分缓解，且未发生严重副作用。无进展生存期为15周。对于一名患有间质性肺疾病的小细胞肺癌患者，使用纳米白蛋白结合型紫杉醇联合卡铂进行二线化疗有效且耐受性良好。
